Literature DB >> 8117603

The clinical spectrum and treatment of primary non-Hodgkin's lymphoma of the stomach.

B G Taal1, J M Burgers, P van Heerde, A A Hart, R Somers.   

Abstract

BACKGROUND: Primary non-Hodgkin's lymphoma (NHL) of the stomach is a rare disease; diagnosis may be difficult and the method of treatment is at debate, especially the role of surgery. We therefore evaluated clinical findings, in particular endoscopic diagnosis and long-term results of various treatment strategies, especially the effect of the stomach-saving procedure with radiotherapy alone, in patients with stage I and II NHL of the stomach over a 20 year period (1970-91). PATIENTS AND METHODS: A series of 119 consecutive patients (71m + 48f, median age 62 years) were studied: 80 patients in stage I and 39 in stage II. Treatment schedules were: group A: standard radiotherapy alone, after clinical staging (n = 46); group B: gastric resection followed by standard radiotherapy (n = 28); group C: various combinations of resection, radiotherapy plus or minus chemotherapy (n = 45). Since 1978 surgery was no longer advocated: our resection rate dropped from 83% to 38%.
RESULTS: Symptoms and signs were non-specific: epigastric pain (81%), nausea (33%), vomiting (24%) and weight loss (66%). Haemorrhage or perforation at presentation were unusual, in 14 (12%) and 5 (4%) cases, respectively. At endoscopy 3 main patterns were recognized: ulceration (34%); diffuse infiltration (18%) and a polypoid mass (37%). Endoscopic biopsies were diagnostic in 92%, including 11% after repeated endoscopy. Treatment results were excellent for stage I: local control in 93%, 5-year survival 70%; in stage II the results were less favorable: 57% and 37%, respectively. Recurrences were only seen in 17 cases, among which 10 cases were extra-abdominal. According to treatment schedule, results were similar in group A (n = 46), with radiotherapy alone, and group B (n = 28), with resection plus radiotherapy, leading to a 5-year overall survival of 71% and 82%, respectively (no significant difference). Severe complications of treatment were infrequent: one perforation, another with a fatal haemorrhage in group A. In group C (n = 45) various individualized schemes were applied, usually palliative either due to large tumour extent or patients of old age and poor condition, leading to a 5-year survival of only 31%.
CONCLUSIONS: Clear patterns were recognized at endoscopy, and diagnosis on endoscopic biopsies was possible in the vast majority (92%); in clinical stage I radiotherapy alone is effective, safe and well tolerated.

Entities:  

Mesh:

Year:  1993        PMID: 8117603     DOI: 10.1093/oxfordjournals.annonc.a058390

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  14 in total

1.  Primary non-Hodgkin's lymphoma of the stomach: three radical modalities of treatment in 75 patients.

Authors:  I B Shchepotin; S R Evans; M Shabahang; V Chorny; R R Buras; V Korobko; A Zadorozhny; R J Nauta
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

2.  18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience.

Authors:  Domenico Albano; Mattia Bertoli; Paola Ferro; Federico Fallanca; Luigi Gianolli; Maria Picchio; Raffaele Giubbini; Francesco Bertagna
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-09-12       Impact factor: 9.236

3.  Primary non-Hodgkin lymphoma of the stomach: endoscopic pattern and prognosis in low versus high grade malignancy in relation to the MALT concept.

Authors:  B G Taal; H Boot; P van Heerde; D de Jong; A A Hart; J M Burgers
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

4.  Malignant gastric lymphoma with spontaneous perforation.

Authors:  Satoko Shimada; Tokichi Gen; Hiroyuki Okamoto
Journal:  BMJ Case Rep       Date:  2013-01-17

5.  [Primary gastric lymphoma].

Authors:  P R Verreet; W U Schmidt; F P Müller
Journal:  Chirurg       Date:  2004-05       Impact factor: 0.955

6.  Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP.

Authors:  Yujin Kobayashi; Yoshihiro Hatta; Atsuko Hojo; Yoshimasa Kura; Yoshihito Uchino; Hiromichi Takahashi; Satomi Kiso; Yukio Hirabayashi; Mai Yagi; Hitomi Kodaira; Daisuke Kurita; Toshitake Tanaka; Katsuhiro Miura; Noriyoshi Iriyama; Sumiko Kobayashi; Umihiko Sawada; Masahiko Sugitani; Jin Takeuchi
Journal:  Exp Ther Med       Date:  2011-11-22       Impact factor: 2.447

7.  111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study.

Authors:  Shuren Li; Amir Kurtaran; Mei Li; Tatjana Traub-Weidinger; Oskar Kienast; Wolfgang Schima; Peter Angelberger; Irene Virgolini; Markus Raderer; Robert Dudczak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-24       Impact factor: 9.236

Review 8.  The diminishing role of surgery in the treatment of gastric lymphoma.

Authors:  Sam S Yoon; Daniel G Coit; Carol S Portlock; Martin S Karpeh
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

Review 9.  Pathological diagnosis is maybe non-essential for special gastric cancer: case reports and review.

Authors:  Wu Song; Chun-Yu Chen; Jian-Bo Xu; Jin-Ning Ye; Liang Wang; Chuang-Qi Chen; Xin-Hua Zhang; Shi-Rong Cai; Wen-Hua Zhan; Yu-Long He
Journal:  World J Gastroenterol       Date:  2013-06-28       Impact factor: 5.742

10.  Primary gastric lymphoma: conservative treatment modality is not inferior to surgery for early-stage disease.

Authors:  Fatih Selçukbiricik; Deniz Tural; Olgun Elicin; Selin Berk; Mustafa Ozgüroğlu; Nuran Bese; Burhan Ferhanoglu
Journal:  ISRN Oncol       Date:  2012-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.